SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the cancellation of purchase orders by Celestial AI, now owned by Marvell, which cited a breach of confidentiality obligations regarding shipping disclosures. The community is sharply divided, with bulls pointing to the company's solid underlying technology and cash position as reasons to buy the dip, while critics and short-sellers argue that management's communication failures and delayed disclosure have severely damaged institutional trust and long-term viability.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as it deepens its footprint in the AI infrastructure race through reports of a massive potential investment in Anthropic and the development of specialized TPU chips to challenge current hardware monopolies. Investors are closely tracking these developments alongside upcoming earnings, fueling community discussions around Alphabet's ability to maintain its AI dominance and cloud-segment growth.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense downward pressure and widespread investor frustration as the stock hits fresh lows, with many in the community debating whether the company is headed for bankruptcy, a reverse split, or a potential take-private deal. While some bulls remain focused on the potential of upcoming vehicle launches and backing from major strategic partners, bears continue to point to relentless dilution and significant cash burn as ongoing red flags.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently the subject of intense community debate as investors weigh strong AI-driven earnings growth and favorable analyst ratings against a recent class-action investigation concerning supply chain news. While many traders view the current volatility as a buying opportunity for a key player in the AI hardware buildout, others remain cautious of price manipulation and the stock's recent struggle to reclaim the $300 level.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is currently the focus of heavy social media speculation and high volatility, with traders highlighting its extremely small float and high borrowing costs as catalysts for potential short-squeeze setups. The community remains deeply divided, balancing excitement over proprietary molecular farming breakthroughs against strong warnings regarding the stock's history of reverse splits and significant cash burn.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is experiencing significant volatility and price swings following a mixed earnings report that missed earnings-per-share expectations despite a revenue beat. The community is actively debating the company's long-term potential as an AI-focused 'pick-and-shovel' play, with some investors viewing the post-earnings pullback as a prime accumulation opportunity while others warn of potential downside due to operational execution risks.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors debate the viability of the company's "Everything Home" turnaround strategy, with the stock seeing volatile price action fueled by ongoing speculation about potential acquisitions and retail turnaround efforts. The community remains deeply divided, with some traders actively looking for short-squeeze setups and bottom-fishing opportunities, while skeptics express frustration over share dilution and the stock's poor long-term performance.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is trending as investors react to a recent earnings report that featured a mixed performance, highlighted by an earnings per share miss alongside a slight revenue beat. The community remains focused on the company's ability to drive sales through value-oriented promotions and digital delivery partnerships despite concerns over weak consumer sentiment and rising industry competition.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca Inc. is facing intense market scrutiny following an 8-K filing that disclosed a patient death in its Phase 1 oncology trial, fueling investor concerns over drug toxicity and trial management. While some retail traders are debating whether the price drop presents a buying opportunity, many community members are aggressively rotating into competitors like Revolution Medicines ($RVMD), citing superior safety profiles and clearer acquisition prospects.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently trending as community members speculate on potential price breakouts, with many sharing long-term price predictions and debating whether the asset is a sleeping giant or a stagnant project. Traders are actively discussing accumulation strategies, analyzing technical patterns, and monitoring volume spikes as they look for signs of a rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.  Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenateâ??s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

CBAY
Cymabay Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CBAY News

CBAYCymabay Therapeutics Inc